Roche Holding AG (OTCMKTS:RHHBY) Receives $57.00 Consensus Price Target from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has earned an average recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $57.00.

A number of equities research analysts have weighed in on RHHBY shares. Morgan Stanley reaffirmed an “underweight” rating on shares of Roche in a report on Wednesday, February 4th. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, January 5th. Wolfe Research reiterated an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. HSBC reiterated a “buy” rating and set a $57.00 price objective on shares of Roche in a research note on Wednesday, December 10th. Finally, TD Cowen restated a “hold” rating on shares of Roche in a research note on Tuesday, February 10th.

Roche Price Performance

OTCMKTS:RHHBY opened at $57.86 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average of $55.83 and a 200-day moving average of $48.43. Roche has a 52 week low of $34.75 and a 52 week high of $60.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Curio Wealth LLC acquired a new stake in Roche during the 3rd quarter valued at $25,000. Oakworth Capital Inc. bought a new stake in shares of Roche during the third quarter worth $57,000. First Horizon Advisors Inc. increased its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after buying an additional 826 shares in the last quarter. Salomon & Ludwin LLC raised its holdings in shares of Roche by 256.6% in the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after buying an additional 2,053 shares during the last quarter. Finally, Atlas Capital Advisors Inc. acquired a new position in Roche during the 4th quarter worth about $192,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.